Clinical efficacy of combined use of docetaxel and bevacizumab in treating hormone refractory prostate cancer
GUAN Weimin
WANG Bin
XU Yansheng
OUYANG Yun
Abstract：Objective To evaluate the efficacy of docetaxel combined with bevacizumab in treating hormone refractory prostate cancer(HRPC).Methods A total of 74 HRPC patients were selected in Navy General Hospital from Apr 2011 to Apr 2013.Seventy-four patients were randomly divided into two groups: chemotherapy group(docetaxel,40 mg/m 2 ) and combined treatment group (docetaxel combined with bevacizumab ,5 mg/kg).A total of 74 subjects were evaluated by the di -sease free survival time,the overall survival time,prostate specific antigen (PSA),the volume of the prostate,the maximal urinary flow rate and the score of Quality of Life .Results The disease free survival time(10 months) and the overall survival time (22 months) on combined treatment group were both longer than chemotherapy group (7 months and 17 months, P<0.05).After treatment, the value of PSA of combined treatment group was lower than that of chemotherapy group (P<0.05). There were no significant difference between the the volume of the prostate ,the maximal urinary flow rate and the score of Quality of Life in two groups (P>0.05).The adverse reaction rate of combined treatment group (64.86%) was higher than that of the chemotherapy group (48.65%, P<0.05). Conclusion The combined application of bevacizumab can prolong the survival time , but the other efficacy still needs further study.With the in-depth application of HRPC translational medicine , immune therapy, targeted therapy and individual therapy will become hot topic of HRPC treatment .
Keywords：BevacizumabHormone refractory prostate cancerChemotherapy
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 143-146 )